WO2018200812A1 - Conjugués d'anticorps comprenant un agoniste de sting - Google Patents
Conjugués d'anticorps comprenant un agoniste de sting Download PDFInfo
- Publication number
- WO2018200812A1 WO2018200812A1 PCT/US2018/029570 US2018029570W WO2018200812A1 WO 2018200812 A1 WO2018200812 A1 WO 2018200812A1 US 2018029570 W US2018029570 W US 2018029570W WO 2018200812 A1 WO2018200812 A1 WO 2018200812A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- alkynyl
- alkenyl
- crc
- independently selected
- Prior art date
Links
- 0 CCCC(CCC)Nc1c2nc[n]([C@@]([C@]3F)O[C@](COP(O)(O[C@@]([C@@](CO4)O[C@]5[n]6c7ncnc(NCC(CNC(OCc(cc8)ccc8NC([C@](CCCNC(N)=O)NC([C@](C(C)C)NC(CCNC(C(CC(O)=O)C(C)(*)CC)=O)=O)=O)=O)=O)O)c7nc6)[C@@]5F)=O)[C@]3OP4(O)=O)c2ncn1 Chemical compound CCCC(CCC)Nc1c2nc[n]([C@@]([C@]3F)O[C@](COP(O)(O[C@@]([C@@](CO4)O[C@]5[n]6c7ncnc(NCC(CNC(OCc(cc8)ccc8NC([C@](CCCNC(N)=O)NC([C@](C(C)C)NC(CCNC(C(CC(O)=O)C(C)(*)CC)=O)=O)=O)=O)=O)O)c7nc6)[C@@]5F)=O)[C@]3OP4(O)=O)c2ncn1 0.000 description 27
- QIAVAVZEYVSHDN-UHFFFAOYSA-N CC(C)C(C(NC(C)C(C)=O)=O)N Chemical compound CC(C)C(C(NC(C)C(C)=O)=O)N QIAVAVZEYVSHDN-UHFFFAOYSA-N 0.000 description 2
- AFBNYAZCLLLHQW-YUMQZZPRSA-N CC(C)(C)OC(N(C1)[C@H](COC(Cl)=O)C[C@@H]1F)=O Chemical compound CC(C)(C)OC(N(C1)[C@H](COC(Cl)=O)C[C@@H]1F)=O AFBNYAZCLLLHQW-YUMQZZPRSA-N 0.000 description 1
- INIMOXBICCYABT-BNIMDDLWSA-N CC(C)(C)OC(N(C1)[C@H](COC(Nc2ncnc3c2nc[n]3[C@@H]2O[C@H](CO[P@@](O)(S)=O)C[C@H]2F)=O)C[C@@H]1F)=O Chemical compound CC(C)(C)OC(N(C1)[C@H](COC(Nc2ncnc3c2nc[n]3[C@@H]2O[C@H](CO[P@@](O)(S)=O)C[C@H]2F)=O)C[C@@H]1F)=O INIMOXBICCYABT-BNIMDDLWSA-N 0.000 description 1
- HHAGINAFGRRHNQ-YPTGHPNCSA-N CC(C)(C)OC(N(C1)[C@H](COC(Nc2ncnc3c2nc[n]3[C@@H]2O[C@H](CO[P@@](OC([C@@H](CO[P@](O)(S)=O)O[C@H]3[n]4c(ncnc5NC(OC[C@H](C[C@@H](C6)F)N6C(OC(C)(C)C)=O)=O)c5nc4)[C@H]3F)(S)=O)C[C@H]2F)=O)C[C@@H]1F)=O Chemical compound CC(C)(C)OC(N(C1)[C@H](COC(Nc2ncnc3c2nc[n]3[C@@H]2O[C@H](CO[P@@](OC([C@@H](CO[P@](O)(S)=O)O[C@H]3[n]4c(ncnc5NC(OC[C@H](C[C@@H](C6)F)N6C(OC(C)(C)C)=O)=O)c5nc4)[C@H]3F)(S)=O)C[C@H]2F)=O)C[C@@H]1F)=O HHAGINAFGRRHNQ-YPTGHPNCSA-N 0.000 description 1
- SZQUXUGZRILXAJ-UHFFFAOYSA-N CC(C)(CCC(N(C)CCN(C)C)=O)SSCCOC(C)=O Chemical compound CC(C)(CCC(N(C)CCN(C)C)=O)SSCCOC(C)=O SZQUXUGZRILXAJ-UHFFFAOYSA-N 0.000 description 1
- WSLVGRCQINWCIX-UHFFFAOYSA-N CC(C)C(C(NC(CCCNC(N)=O)C(Nc1ccc(COC(N(C2)C(COC(Nc3c4nc[n](C(C5F)OC(COP(O)=O)C5OP(OCC(CC5F)OC5[n]5c6ncnc(N)c6nc5)=O)c4ncn3)=O)CC2F)=O)cc1)=O)=O)NC(CCN(C(C=C1)=O)C1=O)=O Chemical compound CC(C)C(C(NC(CCCNC(N)=O)C(Nc1ccc(COC(N(C2)C(COC(Nc3c4nc[n](C(C5F)OC(COP(O)=O)C5OP(OCC(CC5F)OC5[n]5c6ncnc(N)c6nc5)=O)c4ncn3)=O)CC2F)=O)cc1)=O)=O)NC(CCN(C(C=C1)=O)C1=O)=O WSLVGRCQINWCIX-UHFFFAOYSA-N 0.000 description 1
- IGDRULGCCDGCAF-ZETCQYMHSA-N CC(C)[C@@H](C(C)=O)NC Chemical compound CC(C)[C@@H](C(C)=O)NC IGDRULGCCDGCAF-ZETCQYMHSA-N 0.000 description 1
- QIAVAVZEYVSHDN-XPUUQOCRSA-N CC(C)[C@@H](C(N[C@@H](C)C(C)=O)=O)N Chemical compound CC(C)[C@@H](C(N[C@@H](C)C(C)=O)=O)N QIAVAVZEYVSHDN-XPUUQOCRSA-N 0.000 description 1
- XLDWGZOVRLEDHM-ROUUACIJSA-N CC(C)[C@@H](C(N[C@@H](CCCNC(N)=O)C(Nc1ccc(COC(C)=O)cc1)=O)=O)NC Chemical compound CC(C)[C@@H](C(N[C@@H](CCCNC(N)=O)C(Nc1ccc(COC(C)=O)cc1)=O)=O)NC XLDWGZOVRLEDHM-ROUUACIJSA-N 0.000 description 1
- QRXFUYPBMOBORG-IOLLINACSA-N CC(C)[C@@H](C(N[C@@H](CCCNC(N)=O)C(Nc1ccc(COC(N(C)CCOC(Nc2c3nc[n]([C@@H]([C@@H]4F)O[C@H](CO[P@](O)(S)=O)[C@H]4O[P@@](OC[C@H](C[C@H]4F)O[C@H]4[n]4c5ncnc(N)c5nc4)(S)=O)c3ncn2)=O)=O)cc1)=O)=O)NC(CCCCCON)=O Chemical compound CC(C)[C@@H](C(N[C@@H](CCCNC(N)=O)C(Nc1ccc(COC(N(C)CCOC(Nc2c3nc[n]([C@@H]([C@@H]4F)O[C@H](CO[P@](O)(S)=O)[C@H]4O[P@@](OC[C@H](C[C@H]4F)O[C@H]4[n]4c5ncnc(N)c5nc4)(S)=O)c3ncn2)=O)=O)cc1)=O)=O)NC(CCCCCON)=O QRXFUYPBMOBORG-IOLLINACSA-N 0.000 description 1
- HUMYDSJCOUDGBL-ASVYLZMYSA-N CC(C)[C@@H](C(N[C@@H](CCCNC(N)=O)C(Nc1ccc(COCC(N(C)CCOC(/[O]=C/C2[C@H]([n]3c(ncnc4N)c4nc3)O[C@H](CO[P@](O[C@H]3[C@H]([n]4c5ncnc(N)c5nc4)O[C@H](CO4)[C@H]3O)(S)=O)[C@H]2O[P@@]4(S)=O)=O)=O)cc1)=O)=O)NC(CCCCCN(C(C=C1)=O)C1=O)=O Chemical compound CC(C)[C@@H](C(N[C@@H](CCCNC(N)=O)C(Nc1ccc(COCC(N(C)CCOC(/[O]=C/C2[C@H]([n]3c(ncnc4N)c4nc3)O[C@H](CO[P@](O[C@H]3[C@H]([n]4c5ncnc(N)c5nc4)O[C@H](CO4)[C@H]3O)(S)=O)[C@H]2O[P@@]4(S)=O)=O)=O)cc1)=O)=O)NC(CCCCCN(C(C=C1)=O)C1=O)=O HUMYDSJCOUDGBL-ASVYLZMYSA-N 0.000 description 1
- GOLSFPMYASLXJC-UHFFFAOYSA-N CC(OCCN(C)C)=O Chemical compound CC(OCCN(C)C)=O GOLSFPMYASLXJC-UHFFFAOYSA-N 0.000 description 1
- FEGKEUODYZVQRY-UHFFFAOYSA-N CC(OCc(cc1)ccc1NC)=O Chemical compound CC(OCc(cc1)ccc1NC)=O FEGKEUODYZVQRY-UHFFFAOYSA-N 0.000 description 1
- BATVKNMUULFWGG-UHFFFAOYSA-N CC(Oc(c(Cl)cc([S](C)(O)(=O)=O)c1)c1Cl)=O Chemical compound CC(Oc(c(Cl)cc([S](C)(O)(=O)=O)c1)c1Cl)=O BATVKNMUULFWGG-UHFFFAOYSA-N 0.000 description 1
- ZXTVBLZVILLKPM-UHFFFAOYSA-N CC(Oc(c(F)c(c(F)c1F)F)c1F)=O Chemical compound CC(Oc(c(F)c(c(F)c1F)F)c1F)=O ZXTVBLZVILLKPM-UHFFFAOYSA-N 0.000 description 1
- ADYQJXORJLDZQC-UHFFFAOYSA-N CC(Oc(c(F)c(cc1F)F)c1F)=O Chemical compound CC(Oc(c(F)c(cc1F)F)c1F)=O ADYQJXORJLDZQC-UHFFFAOYSA-N 0.000 description 1
- INELDFXPGIZESF-YRMMWGPFSA-N CCC(C)C([C@H](CCCCN)NC(C(C1)(C1C(C)C)NC([C@H](C(C)C)NC)=O)=O)O Chemical compound CCC(C)C([C@H](CCCCN)NC(C(C1)(C1C(C)C)NC([C@H](C(C)C)NC)=O)=O)O INELDFXPGIZESF-YRMMWGPFSA-N 0.000 description 1
- YHWQJTNMKZWBBN-UHFFFAOYSA-N CCc(cc1)ccc1NC Chemical compound CCc(cc1)ccc1NC YHWQJTNMKZWBBN-UHFFFAOYSA-N 0.000 description 1
- DQUJGRKRRRJUJX-UHFFFAOYSA-N CNCC(CN)=O Chemical compound CNCC(CN)=O DQUJGRKRRRJUJX-UHFFFAOYSA-N 0.000 description 1
- KHOPLNXWAWFJOK-MQKDNMFFSA-N CNCCOC(O[C@H]1[C@H]([n]2c(ncnc3N)c3nc2)O[C@H](CO[P@](O[C@H]2[C@H]([n]3c4ncnc(N)c4nc3)O[C@H](CO3)[C@H]2O)(S)=O)[C@H]1O[P@@]3(S)=O)=O Chemical compound CNCCOC(O[C@H]1[C@H]([n]2c(ncnc3N)c3nc2)O[C@H](CO[P@](O[C@H]2[C@H]([n]3c4ncnc(N)c4nc3)O[C@H](CO3)[C@H]2O)(S)=O)[C@H]1O[P@@]3(S)=O)=O KHOPLNXWAWFJOK-MQKDNMFFSA-N 0.000 description 1
- JOQISOPQHIYGBK-UHFFFAOYSA-N CNc1cc(COC)ccc1OC(C(C(C1O)O)O)OC1C(O)=O Chemical compound CNc1cc(COC)ccc1OC(C(C(C1O)O)O)OC1C(O)=O JOQISOPQHIYGBK-UHFFFAOYSA-N 0.000 description 1
- CYTAEEZHBROYQZ-UHFFFAOYSA-N CNc1cc(COC)ccc1OC(C(C1O)O)OC(CO)C1O Chemical compound CNc1cc(COC)ccc1OC(C(C1O)O)OC(CO)C1O CYTAEEZHBROYQZ-UHFFFAOYSA-N 0.000 description 1
- TVVPSEDSHAQKKZ-VYUOYPLNSA-N COc1ccc(C(c2ccccc2)(c(cc2)ccc2OC)OC[C@H]([C@H]([C@H]2O)F)O[C@H]2[n]2c3ncnc(NC(c4ccccc4)=O)c3nc2)cc1 Chemical compound COc1ccc(C(c2ccccc2)(c(cc2)ccc2OC)OC[C@H]([C@H]([C@H]2O)F)O[C@H]2[n]2c3ncnc(NC(c4ccccc4)=O)c3nc2)cc1 TVVPSEDSHAQKKZ-VYUOYPLNSA-N 0.000 description 1
- POBXNFOIKDDPCK-ZKWXMUAHSA-N C[C@@H](C(N[C@@H](C)C(N[C@@H](CC(N)=O)C(C)=O)=O)=O)NC Chemical compound C[C@@H](C(N[C@@H](C)C(N[C@@H](CC(N)=O)C(C)=O)=O)=O)NC POBXNFOIKDDPCK-ZKWXMUAHSA-N 0.000 description 1
- UUWJNBOCAPUTBK-UHFFFAOYSA-O C[n]1c(N=C([NH3+])NC2=O)c2nc1 Chemical compound C[n]1c(N=C([NH3+])NC2=O)c2nc1 UUWJNBOCAPUTBK-UHFFFAOYSA-O 0.000 description 1
- JWAWEQBUZOGIBZ-UHFFFAOYSA-N C[n]1nncc1 Chemical compound C[n]1nncc1 JWAWEQBUZOGIBZ-UHFFFAOYSA-N 0.000 description 1
- TVCLKQLFVRTJTA-UHFFFAOYSA-N C[n]1nncc1O Chemical compound C[n]1nncc1O TVCLKQLFVRTJTA-UHFFFAOYSA-N 0.000 description 1
- BVFVNUZMMPQTFQ-UHFFFAOYSA-N NC(c(cn1)c[n]1I)=O Chemical compound NC(c(cn1)c[n]1I)=O BVFVNUZMMPQTFQ-UHFFFAOYSA-N 0.000 description 1
- NPPQHUKKOGWFQQ-UHFFFAOYSA-N NC(c(nc1)c(N)[n]1I)=O Chemical compound NC(c(nc1)c(N)[n]1I)=O NPPQHUKKOGWFQQ-UHFFFAOYSA-N 0.000 description 1
- RWWWFEXQQGZPLQ-UHFFFAOYSA-N NC(c(nn1)c[n]1I)=O Chemical compound NC(c(nn1)c[n]1I)=O RWWWFEXQQGZPLQ-UHFFFAOYSA-N 0.000 description 1
- ZZYXNRREDYWPLN-UHFFFAOYSA-O Nc1c([NH3+])nccc1 Chemical compound Nc1c([NH3+])nccc1 ZZYXNRREDYWPLN-UHFFFAOYSA-O 0.000 description 1
- OFWIFSZMLOYZJT-USUGAEIBSA-N Nc1ncnc2c1nc[n]2[C@@H]([C@@H]1F)OC(CO[P@](O)(S)=O)C1O[P@](OC[C@H](C[C@H]1F)O[C@H]1Nc1ncnc(NC(OC[C@H](C2)NC[C@H]2F)=O)c1N[U])(S)=O Chemical compound Nc1ncnc2c1nc[n]2[C@@H]([C@@H]1F)OC(CO[P@](O)(S)=O)C1O[P@](OC[C@H](C[C@H]1F)O[C@H]1Nc1ncnc(NC(OC[C@H](C2)NC[C@H]2F)=O)c1N[U])(S)=O OFWIFSZMLOYZJT-USUGAEIBSA-N 0.000 description 1
- SFTNCRGWWOZVJD-OIOLCBQXSA-N Nc1ncnc2c1nc[n]2[C@@H]1OC(CO[P@](O[C@H]([C@@H](COPO)O[C@H]2[n]3c(ncnc4N)c4nc3)[C@H]2F)(S)=O)C[C@H]1F Chemical compound Nc1ncnc2c1nc[n]2[C@@H]1OC(CO[P@](O[C@H]([C@@H](COPO)O[C@H]2[n]3c(ncnc4N)c4nc3)[C@H]2F)(S)=O)C[C@H]1F SFTNCRGWWOZVJD-OIOLCBQXSA-N 0.000 description 1
- BGUXNYJQFLPXCQ-BAJZRUMYSA-N Nc1ncnc2c1nc[n]2[C@@H]1O[C@H](CO[P@](O)(S)=O)C[C@H]1F Chemical compound Nc1ncnc2c1nc[n]2[C@@H]1O[C@H](CO[P@](O)(S)=O)C[C@H]1F BGUXNYJQFLPXCQ-BAJZRUMYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
- C07K9/003—Peptides being substituted by heterocyclic radicals, e.g. bleomycin, phleomycin
Definitions
- n is an integer from 1 to 20;
- n is an integer from 1 to 8.
- n is an integer from 1 to 8.
- the luciferase reporter gene is the 5xlSRE-mlFNb-GL4 reporter gene and the STING-expressing cell is a cell expressing wild-type human STING protein, and optionally the STING agonist activity is determined by the hSTING wt assay described in Table 7.
- the immunoconjugate stimulates IP-10 secretion from a STING-expressing cell targeted by the Ab at an EC50 of 5 nanomolar (nM) or less in an IP-10 secretion assay.
- R 2 and R 3 are connected to form CrCgalkylene, C 2 -C 6 alkenylene, C 2 -C 6 alkynylene, - O-CrCsalkylene, -0-C 2 -C 6 alkenylene, -0-C 2 -C 6 alkynylene, such that when R 2 and R 3 are connected, the 0 is bound at the R 3 position;
- R 4 and R 3 are connected to form CrCsalkylene, C 2 -C 6 alkenylene, C 2 -C 6 alkynylene, - O-CrCsalkylene, -0-C 2 -C 6 alkenylene, -0-C 2 -C 6 alkynylene, such that when R 4 and R 3 are connected, the 0 is bound at the R 3 position;
- R and R are connected to form C ⁇ Csalkylene, C 2 -C 3 alkenylene, C 2 -C 6 alkynylene, -O-CrCealkylene, -0-C 2 -C 6 alkenylene, -0-C 2 -C 6 alkynylene, such that when R 4a and R 3a are connected, the 0 is bound at the R 3a position;
- X D is C, and each Z 4 is N;
- Y 10 is -CH 2 -, -NH-, -0- or -S;
- X 4 is -0(CH 2 ) n SSC(R 12 ) 2 (CH 2 ) n - or -(CH 2 ) n C(R 12 ) 2 SS(CH 2 ) n O-;
- X 5 is where the ** indicates orientation toward the Drug moiety;
- each R 111 is independently selected from H, C r C 6 alkyl, F, CI, -NH 2 , -OCH 3 , -OCH 2 CH 3 , -
- FIG. 7 is a line graph showing the anti-HER2 mAb1 -C1 conjugate inhibits HCC1954 breast tumor growth in mice.
- FIG. 1 1 illustrates certain compounds which can be used as a Drug moiety.
- C 2 -C 6 alkynyl refers to a bivalent straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one triple bond, having from two to six carbon atoms.
- C r C 6 hydroxyalkyl refers to a C 1-6 alkyl radical as defined above, wherein one of the hydrogen atoms of the C 1-6 alkyl radical is replaced by OH.
- hydroxyC ⁇ alkyl include, but are not limited to, hydroxy-methyl, 2-hydroxy-ethyl, 2-hydroxy- propyl, 3-hydroxy-propyl and 5-hydroxy-pentyl
- C 3 -C 8 cycloalkyl refers to a saturated, monocyclic, fused bicyclic, fused tricyclic or bridged polycyclic ring system.
- Non-limiting examples of fused bicyclic or bridged polycyclic ring systems include bicyclo[1 .1 .1 ]pentane, bicyclo[2.1.1]hexane, bicyclo[2.2.1]heptane, bicyclo[3.1.1]heptane, bicyclo[3.2.1 ]octane, bicyclo[2.2.2]octane and adamantanyl.
- Non-limiting examples monocyclic C 3 -C 8 cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl groups.
- the C 2 - C 6 haloalkynyl groups can be diC 2 -C 6 haloalkynyl wherein such C 2 -C 6 haloalkynyl groups can have two halo atoms independently selected from iodo, bromo, chloro or fluoro.
- the C 2 -C 6 haloalkynyl groups can be polyC 2 -C 6 haloalkynyl wherein such C 2 -C 6 haloalkenyl groups can have two or more of the same halo atoms or a combination of two or more different halo atoms.
- heterocyclyl includes partially saturated or aromatic monocyclic or fused bicyclic heterocyclyl containing from 5-10 ring members selected from carbon atoms and 1 to 5 heteroatoms, and each heteroatoms is independently selected from O, N or S. In a preferred embodiment, the heteroatoms are nitrogen.
- substituents include oxo, halo, C 1-6 alkyl, C ⁇ alkoxy, amino, C ⁇ alkylamino, di-C ⁇ alkylamino.
- the heterocyclic group can be attached at a heteroatom or a carbon atom.
- Heterocyclyl also includes 6-membered monocyclic partially saturated ring having 1-3 heteroatoms (preferably nitrogen).
- Examples of partially saturated monocyclic heterocyclyl are pyrimidine-one and pyrimidine-dione, specifically pyrimidin-2(1 H)-one and pyrimidin-1 -yl-2,4(1 H, 3H)-dione.
- tautomer is used to designate 2 molecules with the same molecular formula but different connectivity, which can interconvert in a rapid equilibrium.
- phosporothioic acid and phosphoric acid moieties can exist in the respective equilibrium as shown below.
- VH heavy chain variable domain
- HCDR1 e.g., insertion(s) after position 35
- homologous refers to the subunit sequence identity between two polymeric molecules, e.g., between two nucleic acid molecules, such as, two DNA molecules or two RNA molecules, or between two polypeptide molecules.
- two nucleic acid molecules such as, two DNA molecules or two RNA molecules
- polypeptide molecules between two polypeptide molecules.
- a subunit position in both of the two molecules is occupied by the same monomeric subunit; e.g., if a position in each of two DNA molecules is occupied by adenine, then they are homologous or identical at that position.
- the homology between two sequences is a direct function of the number of matching or homologous positions; e.g., if half (e.g., five positions in a polymer ten subunits in length) of the positions in two sequences are homologous, the two sequences are 50% homologous; if 90% of the positions (e.g., 9 of 10), are matched or homologous, the two sequences are 90% homologous.
- Percentage of "sequence identity" can be determined by comparing two optimally aligned sequences over a comparison window, where the fragment of the amino acid sequence in the comparison window may comprise additions or deletions (e.g., gaps or overhangs) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences.
- the percentage can be calculated by determining the number of positions at which the identical amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison, and multiplying the result by 100 to yield the percentage of sequence identity.
- the output is the percent identity of the subject sequence with respect to the query sequence.
- the percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.
- an optical isomer or "a stereoisomer”, as used herein, refers to any of the various stereo isomeric configurations which may exist for a given compound of the present invention and includes geometric isomers. It is understood that a substituent may be attached at a chiral center of a carbon atom.
- the term “chiral” refers to molecules which have the property of non-superimposability on their mirror image partner, while the term “achiral” refers to molecules which are superimposable on their mirror image partner. Therefore, the invention includes enantiomers, diastereomers or racemates of the compound. "Enantiomers” are a pair of stereoisomers that are non- superimposable mirror images of each other.
- P-cadherin also refers to proteins and amino acid sequences that over their full length have at least about 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with the amino acid sequence of the above GenBank accession Nos.
- pharmaceutically acceptable salt refers to a salt which does not abrogate the biological activity and properties of the compounds of the invention, and does not cause significant irritation to a subject to which it is administered.
- STING agonist refers to a compound or antibody conjugate capable of binding to STING and activating STING.
- Activation of STING activity may include, for example, stimulation of inflammatory cytokines, including interferons, such as type 1 interferons, including IFN-a, IFN- ⁇ , type 3 interferons, e.g., IFN , IP10, TNF, IL-6, CXCL9, CCL4, CXCL11 , CCL5, CCL3, or CCL8.
- interferons such as type 1 interferons, including IFN-a, IFN- ⁇ , type 3 interferons, e.g., IFN , IP10, TNF, IL-6, CXCL9, CCL4, CXCL11 , CCL5, CCL3, or CCL8.
- terapéuticaally effective amount or “therapeutically effective dose” interchangeably refers to an amount sufficient to effect the desired result (i.e., reduction or inhibition of an enzyme or a protein activity, amelioration of symptoms, alleviation of symptoms or conditions, delay of disease progression, a reduction in tumor size, inhibition of tumor growth, prevention of metastasis, inhibition or prevention of viral, bacterial, fungal or parasitic infection).
- a therapeutically effective amount does not induce or cause undesirable side effects.
- a therapeutically effective amount induces or causes side effects but only those that are acceptable by the healthcare providers in view of a patient's condition.
- a therapeutically effective amount can be determined by first administering a low dose, and then incrementally increasing that dose until the desired effect is achieved.
- Y 7 is 0 or S
- CrCshaloalkyl C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, -0(C r C 6 alkyl), -0(C 2 -C 3 alkenyl), - 0(C 2 -C 6 alkynyl), -OC(0)OCrC 6 alkyl, -OC(0)OC 2 -C 6 alkenyl, -OC(0)OC 2 -C 6 alkynyl, - OC(0)C r C 6 alkyl, -OC(0)C 2 -C 6 alkenyl and -OC(0)C 2 -C 6 alkynyl of R 3 are substituted by 0,1 , 2 or 3 substituents independently selected from F, CI, Br, I, OH, CN, and N 3 ;
- R 3a and R 6a are connected to form Crdalkylene, C 2 -C 6 alkenylene, C 2 - C 6 alkynylene, -0-C r C 6 alkylene, -0-C 2 -C 6 alkenylene, -0-C 2 -C 6 alkynylene, such that when R 3a and R 6a are connected, the O is bound at the R 3a position;
- R 2 and R 3 are connected to form d-Calkylene, C 2 -C 6 alkenylene, C 2 -
- R 5 and R 6 are connected to form C ⁇ Cealkylene, C 2 -C 6 alkenylene, C 2 - C 6 alkynylene, -0-C r C 6 alkylene, -0-C 2 -C 6 alkenylene, -0-C 2 -C 6 alkynylene, such that when R 5 and R 6 are connected, the 0 is bound at the R 5 position;
- R 5a and R 7a are connected to form CrCsalkylene, C 2 -C 6 alkenylene, C 2 - C 6 alkynylene, -0-C r C 6 alkylene, -0-C 2 -C 6 alkenylene, -0-C 2 -C 6 alkynylene, such that when R 5a and R 7a are connected, the O is bound at the R 5a position;
- R 6 and R 6a are H
- R 8 , R 9 , R 8a and R 9a are independently H or C r C 6 alkyl
- Embodiment 1 , 2 or 3 wherein:
- R 8 , R 9 , R 8a and R 9a are independently H or C r C 6 alkyl
- Y 9 and Y 10 are 0 or S;
- Embodiment 12 A compound of Formula (E), Formula (E-1) or Formula (E-2) of
- Embodiment 1 , 2 or 3 wherein:
- R 3a and R 4a is H and the other is selected from the group consisting of H, -OH, F, CI, Br, I, D, CD 3 , CN, N 3 , C r C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, CrCehaloalkyl, C 2 -
- C 6 alkyl, -OC(0)OC 2 -C 6 alkenyl, -OC(0)OC 2 -C 6 alkynyl, -OC ⁇ CrCealkyl, -OC(0)C 2 - C 6 alkenyl and -OC(0)C 2 -C 6 alkynyl of R 3 or R 4 are substituted by 0, 1 , 2 or 3 substituents independently selected from F, CI, Br, I, OH, CN, and N 3 , and one of R 5 and R 7 is H and the other is selected from the group consisting of H, -OH, F, CI, Br, I, D, CD 3 , CN, N 3 , C r C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C r C 6 haloalkyl, C 2 - C 6 haloalkenyl, C 2 -C 6 haloalkynyl, -0(C r Csal
- Embodiment 1 1, 2, 3 or 12 wherein:
- Y 5 is O or S
- Y 7 is O or S
- R 3a , R a is H and the other is H, OH, OCH 3 or F;
- R 3 , R 4 is H and the other is H, OH, OCH 3 or F;
- R 5 and R 7 are H and the other is H, OH, OCH 3 or F, and
- Embodiment 14 A compound of Formula (F), Formula (F-1) or Formula (F-2) of
- R 2 and R 2a are H; each R e and R ea are H;
- each R 7a and R 7 are H;
- R 8 , R 9 , R 8a and R 9a are independently H or C r C 6 alkyl
- R 3a and R a is H and the other is selected from the group consisting of H, -OH, F, CI, Br, I, D, CD 3 , CN, N 3 , C r C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C r C 6 haloalkyl, C 2 -
- C 6 alkenyl and -OC(0)C 2 -C 6 alkynyl of R 3 or R 4 are substituted by 0, 1 , 2 or 3 substituents independently selected from F, CI, Br, I, OH, CN, and N 3 , and
- R 5 is selected from the group consisting of H, -OH, F, CI, Br, I, D, CD 3 , CN, N 3 , C r
- Embodiment 15 A compound of Formula (F), Formula (F-1) or Formula (F-2) of
- Embodiment 1 1, 2, 3 or 12 wherein:
- Y 1 and Y 2 are 0, CH 2 or S;
- each Y 3 is OH, 0 " , OR 10 , N(R 10 ) 2 , SH or S " ;
- R 2 , R 2a , R 6 , R 6a , R 6 , R 7 and R 7a are H;
- R 3 , R 4 is H and the other is H, OH, OCH 3 or F;
- R is substituted with 0, 1 , 2 or 3 substituents independently selected from F, CI, Br, OH, SH, NH 2 , D, CD 3 , C r C s alkyl, C r
- Y 3 is OH, 0 " , OR 10 , N(R 10 ) 2 , SH or S " ;
- each R 6 is independently selected from the group consisting of H, -OH, F, CI, Br, I, D, CD 3 , CN, N 3 , C r C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, CrCehaloalkyl, C 2 -C 3 haloalkenyl, C 2 -
- CrCshaloalkyl C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, -0(C r C 6 alkyl), -0(C 2 -C 3 alkenyl), - 0(C 2 -C 6 alkynyl), -OC(0)OCrC 6 alkyl, -0C(0)0C 2 -C 6 alkenyl, -0C(0)0C 2 -C 6 alkynyl, - OC(0)C r C 6 alkyl, -OC(0)C 2 -C 6 alkenyl and -OC(0)C 2 -C 6 alkynyl of R s are substituted by 0, 1 , 2 or 3 substituents independently selected from F, CI, Br, I, OH, CN, and N 3 ;
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019558397A JP2020517700A (ja) | 2017-04-28 | 2018-04-26 | Stingアゴニストを含む抗体コンジュゲート |
EP18724677.2A EP3615080A1 (fr) | 2017-04-28 | 2018-04-26 | Conjugués d'anticorps comprenant un agoniste de sting |
CN201880043438.4A CN110799218A (zh) | 2017-04-28 | 2018-04-26 | 包含sting激动剂的抗体缀合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762491879P | 2017-04-28 | 2017-04-28 | |
US62/491,879 | 2017-04-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018200812A1 true WO2018200812A1 (fr) | 2018-11-01 |
Family
ID=62165655
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2018/029570 WO2018200812A1 (fr) | 2017-04-28 | 2018-04-26 | Conjugués d'anticorps comprenant un agoniste de sting |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP3615080A1 (fr) |
JP (1) | JP2020517700A (fr) |
CN (1) | CN110799218A (fr) |
AR (1) | AR113224A1 (fr) |
WO (1) | WO2018200812A1 (fr) |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020089815A1 (fr) * | 2018-10-31 | 2020-05-07 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste de sting |
WO2020092617A1 (fr) * | 2018-10-31 | 2020-05-07 | Novartis Ag | Conjugués d'anticorps dc-sign comprenant des agonistes de sting |
WO2020227159A2 (fr) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Métodes de modulation de l'activité immunitaire |
WO2020229982A1 (fr) | 2019-05-10 | 2020-11-19 | Takeda Pharmaceutical Company Limited | Conjugués anticorps-médicament |
WO2020236817A2 (fr) | 2019-05-20 | 2020-11-26 | Novartis Ag | Conjugués anticorps-médicament inhibiteurs de mcl-1 et méthodes d'utilisation |
CN112439075A (zh) * | 2019-09-04 | 2021-03-05 | 乐高化学生物科学股份有限公司 | 包含抗人类ror1抗体的抗体-药物结合物和其用途 |
WO2021046426A1 (fr) * | 2019-09-06 | 2021-03-11 | Sperovie Biosciences, Inc. | Agonistes de sting dinucléotidiques cycliques attachés à un pd-1 ou à des anticorps ctla-4 |
US10980825B2 (en) | 2016-12-01 | 2021-04-20 | Takeda Pharmaceutical Company Limited | Cyclic dinucleotide |
US11033635B2 (en) | 2019-07-19 | 2021-06-15 | Immunesensor Therapeutics, Inc. | Antibody-STING agonist conjugates and their use in immunotherapy |
WO2021132166A1 (fr) * | 2019-12-23 | 2021-07-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Procédé de production d'un conjugué anticorps-médicament à base d'éribuline |
US20210205348A1 (en) * | 2018-06-01 | 2021-07-08 | Eisai R&D Management Co., Ltd. | Methods for the Treatment of Bladder Cancer |
CN113195541A (zh) * | 2018-12-21 | 2021-07-30 | 诺华股份有限公司 | 针对pmel17的抗体及其缀合物 |
WO2021177438A1 (fr) * | 2020-03-06 | 2021-09-10 | 第一三共株式会社 | Conjugué anticorps-médicament comprenant un nouveau dérivé de dinucléotide cyclique |
WO2021202984A1 (fr) * | 2020-04-02 | 2021-10-07 | Mersana Therapeutics, Inc. | Conjugués anticorps-médicament comprenant des agonistes de sting |
WO2021206158A1 (fr) | 2020-04-10 | 2021-10-14 | 小野薬品工業株式会社 | Méthode de cancérothérapie |
US11155567B2 (en) | 2019-08-02 | 2021-10-26 | Mersana Therapeutics, Inc. | Sting agonist compounds and methods of use |
WO2021216572A1 (fr) | 2020-04-20 | 2021-10-28 | Massachusetts Institute Of Technology | Compositions lipidiques pour l'administration de composés agonistes de sting et leurs utilisations |
WO2021232019A1 (fr) | 2020-05-15 | 2021-11-18 | Immunesensor Therapeutics, Inc. | Polythérapies à agoniste de sting assorties d'inhibiteurs de points de contrôle immunitaires |
WO2022097117A1 (fr) | 2020-11-09 | 2022-05-12 | Takeda Pharmaceutical Company Ltd. | Conjugués anticorps-médicament |
WO2022217022A1 (fr) | 2021-04-10 | 2022-10-13 | Profoundbio Us Co. | Agents de liaison à folr1, conjugués de ceux-ci et leurs procédés d'utilisation |
JP2022545006A (ja) * | 2019-08-21 | 2022-10-24 | ザ スクリプス リサーチ インスティテュート | インターフェロン遺伝子の刺激因子stingの二環式アゴニスト |
WO2022223619A1 (fr) | 2021-04-20 | 2022-10-27 | Institut Curie | Compositions et procédés destinés à être utilisés en immunothérapie |
WO2022226317A1 (fr) | 2021-04-23 | 2022-10-27 | Profoundbio Us Co. | Anticorps anti-cd70, leurs conjugués et leurs procédés d'utilisation |
US11542293B2 (en) | 2017-11-10 | 2023-01-03 | Takeda Pharmaceutical Company Limited | Sting modulator compounds, and methods of making and using |
WO2023280227A2 (fr) | 2021-07-06 | 2023-01-12 | Profoundbio Us Co. | Lieurs, lieurs de médicament, conjugués de ceux-ci et leurs méthodes d'utilisation |
WO2023004440A2 (fr) | 2021-07-23 | 2023-01-26 | Immunesensor Therapeutics, Inc. | Polythérapies à base d'agonistes de sting comprenant des cytokines |
US11584774B2 (en) | 2017-09-11 | 2023-02-21 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
WO2023109942A1 (fr) * | 2021-12-17 | 2023-06-22 | Jacobio Pharmaceuticals Co., Ltd. | Constructions lieurs-composés comprenant de nouveaux composés utiles en tant qu'agonistes de sting et leurs utilisations |
US11707531B2 (en) | 2017-09-11 | 2023-07-25 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
US11730817B2 (en) * | 2017-12-29 | 2023-08-22 | Invivogen | Pro-cyclic dinucleotides and pro-cyclic dinucleotide conjugates for cytokine induction |
US11787833B2 (en) | 2019-05-09 | 2023-10-17 | Aligos Therapeutics, Inc. | Modified cyclic dinucleoside compounds as sting modulators |
US11827703B2 (en) | 2018-05-09 | 2023-11-28 | Legochem Biosciences, Inc. | Compositions and methods related to anti-CD19 antibody drug conjugates |
WO2024020164A2 (fr) | 2022-07-21 | 2024-01-25 | Firefly Bio, Inc. | Agonistes du récepteur des glucocorticoïdes et leurs conjugués |
JP7440504B2 (ja) | 2018-07-10 | 2024-02-28 | エフ-スター・セラピューティクス・インコーポレイテッド | 疾患を治療するための化合物、組成物及び方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111592570B (zh) * | 2020-05-15 | 2022-04-29 | 清华大学 | 新型sting激动剂及其制备方法和应用 |
Citations (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6703199B1 (en) | 1997-06-12 | 2004-03-09 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
WO2007070598A2 (fr) | 2005-12-13 | 2007-06-21 | Spring Bank | Promedicaments nucleotide et oligonucleotide |
US20090274713A1 (en) | 2008-04-30 | 2009-11-05 | Immunogen Inc. | Cross-linkers and their uses |
WO2014083505A1 (fr) | 2012-11-30 | 2014-06-05 | Novartis Ag | Procédés pour la fabrication de conjugués à partir de protéines contenant du disulfure |
WO2014093936A1 (fr) | 2012-12-13 | 2014-06-19 | Aduro Biotech, Inc. | Compositions comprenant des dinucléotides cycliques de purine présentant des stéréochimies définies et procédés pour leur préparation et leur utilisation |
WO2014124316A2 (fr) | 2013-02-08 | 2014-08-14 | Irm Llc | Sites spécifiques de modification d'anticorps pour fabriquer des immunoconjugués |
WO2014179335A1 (fr) | 2013-04-29 | 2014-11-06 | Memorial Sloan Kettering Cancer Center | Compositions et procédés pour altérer la signalisation par un second messager |
WO2014189805A1 (fr) | 2013-05-18 | 2014-11-27 | Auro Biotech, Inc. | Compositions et procédés d'activation de la signalisation dépendante de « stimulateur de gènes d'interféron » |
WO2015074145A1 (fr) | 2013-11-22 | 2015-05-28 | Brock University | Utilisation de dinucléotides cycliques fluorés comme adjuvants de vaccin oral |
US20150158886A1 (en) | 2013-12-06 | 2015-06-11 | Rutgers, The State University Of New Jersey | Cyclic dinucleosides |
WO2015185565A1 (fr) | 2014-06-04 | 2015-12-10 | Glaxosmithkline Intellectual Property Development Limited | Di-nucléotides cycliques utilisés comme modulateurs de sting |
WO2016096174A1 (fr) | 2014-12-16 | 2016-06-23 | Invivogen | Dinucléotides cycliques fluorés utilisables en vue de l'induction des cytokines |
WO2016145102A1 (fr) | 2015-03-10 | 2016-09-15 | Aduro Biotech, Inc. | Compositions et procédés d'activation de la signalisation dépendante de « stimulateur de gènes d'interféron » |
WO2016161372A1 (fr) * | 2015-04-01 | 2016-10-06 | President And Fellows Of Harvard College | Immunoconjugués pour la programmation ou reprogrammation de cellules |
WO2017004499A1 (fr) | 2015-07-02 | 2017-01-05 | Spring Bank Pharmaceuticals, Inc. | Compositions et méthodes de traitement d'une infection virale |
WO2017011622A1 (fr) | 2015-07-14 | 2017-01-19 | Spring Bank Pharmaceuticals, Inc. | Composés et compositions qui induisent rig-i et d'autres récepteurs de reconnaissance de motifs |
WO2017027645A1 (fr) | 2015-08-13 | 2017-02-16 | Merck Sharp & Dohme Corp. | Composés di-nucléotidiques cycliques en tant qu'agonistes de sting |
CN106540256A (zh) * | 2016-03-27 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | 环二核苷酸-脂质体偶联单克隆抗体在抗肿瘤中的应用 |
WO2017100305A2 (fr) * | 2015-12-07 | 2017-06-15 | Opi Vi - Ip Holdco Llc | Composition de conjugués d'agonistes-constructions d'anticorps et leurs procédés d'utilisation |
WO2018009648A1 (fr) | 2016-07-06 | 2018-01-11 | Sperovie Biosciences, Inc. | Composés, compositions et méthodes de traitement de maladie |
WO2018009652A1 (fr) | 2016-07-06 | 2018-01-11 | Sperovie Biosciences, Inc. | Composés, compositions et méthodes de traitement de maladie |
WO2018013908A1 (fr) | 2016-07-15 | 2018-01-18 | Sperovie Biosciences, Inc. | Composés, compositions et méthodes de traitement de maladie |
WO2018013887A1 (fr) | 2016-07-15 | 2018-01-18 | Sperovie Biosciences, Inc. | Composés, compositions et méthodes de traitement de maladie |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3328418A1 (fr) * | 2015-07-29 | 2018-06-06 | Novartis AG | Traitements combinés comprenant des molécules d'anticorps qui se lient à pd-1 |
-
2018
- 2018-04-25 AR ARP180101063A patent/AR113224A1/es unknown
- 2018-04-26 EP EP18724677.2A patent/EP3615080A1/fr not_active Withdrawn
- 2018-04-26 CN CN201880043438.4A patent/CN110799218A/zh active Pending
- 2018-04-26 JP JP2019558397A patent/JP2020517700A/ja active Pending
- 2018-04-26 WO PCT/US2018/029570 patent/WO2018200812A1/fr active Application Filing
Patent Citations (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6703199B1 (en) | 1997-06-12 | 2004-03-09 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
WO2007070598A2 (fr) | 2005-12-13 | 2007-06-21 | Spring Bank | Promedicaments nucleotide et oligonucleotide |
US20090274713A1 (en) | 2008-04-30 | 2009-11-05 | Immunogen Inc. | Cross-linkers and their uses |
WO2014083505A1 (fr) | 2012-11-30 | 2014-06-05 | Novartis Ag | Procédés pour la fabrication de conjugués à partir de protéines contenant du disulfure |
WO2014093936A1 (fr) | 2012-12-13 | 2014-06-19 | Aduro Biotech, Inc. | Compositions comprenant des dinucléotides cycliques de purine présentant des stéréochimies définies et procédés pour leur préparation et leur utilisation |
WO2014124316A2 (fr) | 2013-02-08 | 2014-08-14 | Irm Llc | Sites spécifiques de modification d'anticorps pour fabriquer des immunoconjugués |
WO2014179335A1 (fr) | 2013-04-29 | 2014-11-06 | Memorial Sloan Kettering Cancer Center | Compositions et procédés pour altérer la signalisation par un second messager |
WO2014189805A1 (fr) | 2013-05-18 | 2014-11-27 | Auro Biotech, Inc. | Compositions et procédés d'activation de la signalisation dépendante de « stimulateur de gènes d'interféron » |
WO2015074145A1 (fr) | 2013-11-22 | 2015-05-28 | Brock University | Utilisation de dinucléotides cycliques fluorés comme adjuvants de vaccin oral |
US20150158886A1 (en) | 2013-12-06 | 2015-06-11 | Rutgers, The State University Of New Jersey | Cyclic dinucleosides |
US9315523B2 (en) | 2013-12-06 | 2016-04-19 | Rutgers, The State University Of New Jersey | Cyclic dinucleosides |
WO2015185565A1 (fr) | 2014-06-04 | 2015-12-10 | Glaxosmithkline Intellectual Property Development Limited | Di-nucléotides cycliques utilisés comme modulateurs de sting |
WO2016096174A1 (fr) | 2014-12-16 | 2016-06-23 | Invivogen | Dinucléotides cycliques fluorés utilisables en vue de l'induction des cytokines |
WO2016145102A1 (fr) | 2015-03-10 | 2016-09-15 | Aduro Biotech, Inc. | Compositions et procédés d'activation de la signalisation dépendante de « stimulateur de gènes d'interféron » |
WO2016161372A1 (fr) * | 2015-04-01 | 2016-10-06 | President And Fellows Of Harvard College | Immunoconjugués pour la programmation ou reprogrammation de cellules |
WO2017004499A1 (fr) | 2015-07-02 | 2017-01-05 | Spring Bank Pharmaceuticals, Inc. | Compositions et méthodes de traitement d'une infection virale |
WO2017011622A1 (fr) | 2015-07-14 | 2017-01-19 | Spring Bank Pharmaceuticals, Inc. | Composés et compositions qui induisent rig-i et d'autres récepteurs de reconnaissance de motifs |
WO2017027645A1 (fr) | 2015-08-13 | 2017-02-16 | Merck Sharp & Dohme Corp. | Composés di-nucléotidiques cycliques en tant qu'agonistes de sting |
WO2017027646A1 (fr) | 2015-08-13 | 2017-02-16 | Merck Sharp & Dohme Corp. | Composés de di-nucléotide cyclique en tant qu'agonistes sting (stimulateur de gène interféron) |
WO2017100305A2 (fr) * | 2015-12-07 | 2017-06-15 | Opi Vi - Ip Holdco Llc | Composition de conjugués d'agonistes-constructions d'anticorps et leurs procédés d'utilisation |
CN106540256A (zh) * | 2016-03-27 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | 环二核苷酸-脂质体偶联单克隆抗体在抗肿瘤中的应用 |
WO2018009648A1 (fr) | 2016-07-06 | 2018-01-11 | Sperovie Biosciences, Inc. | Composés, compositions et méthodes de traitement de maladie |
WO2018009652A1 (fr) | 2016-07-06 | 2018-01-11 | Sperovie Biosciences, Inc. | Composés, compositions et méthodes de traitement de maladie |
WO2018013908A1 (fr) | 2016-07-15 | 2018-01-18 | Sperovie Biosciences, Inc. | Composés, compositions et méthodes de traitement de maladie |
WO2018013887A1 (fr) | 2016-07-15 | 2018-01-18 | Sperovie Biosciences, Inc. | Composés, compositions et méthodes de traitement de maladie |
Non-Patent Citations (38)
Title |
---|
"GenBank", Database accession no. AA14462 |
"GenBank", Database accession no. NG_007503.1 |
"GenBank", Database accession no. NG_009096 |
"GenBank", Database accession no. NG_009096.1 |
"GenBank", Database accession no. NM_001793.4 |
"GenBank", Database accession no. NP _001784 |
"GenBank", Database accession no. NP_ 001784 |
"GenBank", Database accession no. NP_ 001784.2 |
"GenBank", Database accession no. NP_001784 |
"GenBank", Database accession no. NP_001784.2 |
"Remington's Pharmaceutical Sciences, 18th ed.", 1990, MACK PRINTING COMPANY, pages: 1289 - 1329 |
AI-LAZIKANI ET AL., J. MAL. BIOL., vol. 273, 1997, pages 927 - 948 |
AI-LAZIKANI ET AL., JMB, vol. 273, 1997, pages 927 - 948 |
AL LAZIKANI ET AL., J. MOL. BIO., vol. 273, 1997, pages 927 948 |
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 10 |
ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 3402 |
ANGEW. CHEM. INT. ED., vol. 54, 2015, pages 7492 - 7509 |
BIOCONJUGATE CHEMISTRY, vol. 26, 2015, pages 2554 - 2562 |
CHEN ET AL., CELL, vol. 147, 2011, pages 436 - 446 |
CHOTHIA ET AL., J. MOL. BIOL., vol. 196, 1987, pages 901 - 917 |
CHOTHIA ET AL., NATURE, vol. 342, 1989, pages 877 - 883 |
DUCRY ET AL., BIOCONIUQATE CHEM., vol. 21, 2010, pages 5 - 13 |
E. MEYERS; W. MILLER, CABIOS, vol. 4, 1989, pages 11 - 17 |
HOLLINGER; HUDSON, NATURE BIOTECHNOLOGY, vol. 23, 2005, pages 1126 - 1136 |
ISHIKAWA; BARBER, NATURE, vol. 455, no. 7213, 2008, pages 674 - 678 |
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES |
KABAT ET AL.: "Sequences of Proteins of Immunological Interest, 5th ed.", 1991, PUBLIC HEALTH SERVICE, NATIONAL INSTITUTES OF HEALTH |
KATO ET AL., PLOS ONE, vol. 8, no. 10, 2013, pages e76983 |
KNAPPIK ET AL., J MOL BIOL, vol. 296, 2000, pages 57 - 86 |
LEFRANC, M.-P. ET AL., DEV. COMP. IMMUNOL., vol. 27, 2003, pages 55 - 77 |
LEFRANC, M.-P., THE IMMUNOLOGIST, vol. 7, 1999, pages 132 - 136 |
NEEDLEMAN; WUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 444 - 453 |
OU ET AL., PNAS, vol. 108, no. 26, 2011, pages 10437 - 42 |
OUYANG ET AL., IMMUNITY, vol. 36, 2012, pages 1073 |
STUDIER, PROTEIN EXPR PURIF., vol. 41, no. 1, May 2005 (2005-05-01), pages 207 - 34 |
TROUT ET AL., PROC. NATL. ACAD. SCI. USA, vol. 79, 1982, pages 626 - 629 |
UMEMOTO ET AL., INT. J. CANCER, vol. 43, 1989, pages 677 - 684 |
YI, PLOS ONE, vol. 8, no. 10, 21 October 2013 (2013-10-21), pages e77846 |
Cited By (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11666594B2 (en) | 2016-12-01 | 2023-06-06 | Takeda Pharmaceutical Company Limited | Antibody-drug conjugates comprising a cyclic dinucleotide |
US10980825B2 (en) | 2016-12-01 | 2021-04-20 | Takeda Pharmaceutical Company Limited | Cyclic dinucleotide |
US11707531B2 (en) | 2017-09-11 | 2023-07-25 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
US11584774B2 (en) | 2017-09-11 | 2023-02-21 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
US11542293B2 (en) | 2017-11-10 | 2023-01-03 | Takeda Pharmaceutical Company Limited | Sting modulator compounds, and methods of making and using |
US11730817B2 (en) * | 2017-12-29 | 2023-08-22 | Invivogen | Pro-cyclic dinucleotides and pro-cyclic dinucleotide conjugates for cytokine induction |
US11827703B2 (en) | 2018-05-09 | 2023-11-28 | Legochem Biosciences, Inc. | Compositions and methods related to anti-CD19 antibody drug conjugates |
US20210205348A1 (en) * | 2018-06-01 | 2021-07-08 | Eisai R&D Management Co., Ltd. | Methods for the Treatment of Bladder Cancer |
JP7440504B2 (ja) | 2018-07-10 | 2024-02-28 | エフ-スター・セラピューティクス・インコーポレイテッド | 疾患を治療するための化合物、組成物及び方法 |
WO2020089815A1 (fr) * | 2018-10-31 | 2020-05-07 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste de sting |
WO2020092617A1 (fr) * | 2018-10-31 | 2020-05-07 | Novartis Ag | Conjugués d'anticorps dc-sign comprenant des agonistes de sting |
CN113195541A (zh) * | 2018-12-21 | 2021-07-30 | 诺华股份有限公司 | 针对pmel17的抗体及其缀合物 |
WO2020227159A2 (fr) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Métodes de modulation de l'activité immunitaire |
US11376272B2 (en) * | 2019-05-03 | 2022-07-05 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
US11787833B2 (en) | 2019-05-09 | 2023-10-17 | Aligos Therapeutics, Inc. | Modified cyclic dinucleoside compounds as sting modulators |
WO2020229982A1 (fr) | 2019-05-10 | 2020-11-19 | Takeda Pharmaceutical Company Limited | Conjugués anticorps-médicament |
CN114173824A (zh) * | 2019-05-10 | 2022-03-11 | 武田药品工业株式会社 | 抗体药物缀合物 |
WO2020236817A2 (fr) | 2019-05-20 | 2020-11-26 | Novartis Ag | Conjugués anticorps-médicament inhibiteurs de mcl-1 et méthodes d'utilisation |
US11213592B2 (en) | 2019-07-19 | 2022-01-04 | Immunesensor Therapeutics, Inc. | Antibody-sting agonist conjugates and their use in immunotherapy |
US11033635B2 (en) | 2019-07-19 | 2021-06-15 | Immunesensor Therapeutics, Inc. | Antibody-STING agonist conjugates and their use in immunotherapy |
US11155567B2 (en) | 2019-08-02 | 2021-10-26 | Mersana Therapeutics, Inc. | Sting agonist compounds and methods of use |
US11939343B2 (en) | 2019-08-02 | 2024-03-26 | Mersana Therapeutics, Inc. | Sting agonist compounds and methods of use |
JP2022545006A (ja) * | 2019-08-21 | 2022-10-24 | ザ スクリプス リサーチ インスティテュート | インターフェロン遺伝子の刺激因子stingの二環式アゴニスト |
JP7414965B2 (ja) | 2019-08-21 | 2024-01-16 | ザ スクリプス リサーチ インスティテュート | インターフェロン遺伝子の刺激因子stingの二環式アゴニスト |
CN112439075A (zh) * | 2019-09-04 | 2021-03-05 | 乐高化学生物科学股份有限公司 | 包含抗人类ror1抗体的抗体-药物结合物和其用途 |
WO2021046426A1 (fr) * | 2019-09-06 | 2021-03-11 | Sperovie Biosciences, Inc. | Agonistes de sting dinucléotidiques cycliques attachés à un pd-1 ou à des anticorps ctla-4 |
WO2021132166A1 (fr) * | 2019-12-23 | 2021-07-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Procédé de production d'un conjugué anticorps-médicament à base d'éribuline |
WO2021177438A1 (fr) * | 2020-03-06 | 2021-09-10 | 第一三共株式会社 | Conjugué anticorps-médicament comprenant un nouveau dérivé de dinucléotide cyclique |
US20220378749A1 (en) * | 2020-04-02 | 2022-12-01 | Mersana Therapeutics, Inc. | Antibody drug conjugates comprising sting agonists |
EP4218826A3 (fr) * | 2020-04-02 | 2023-10-25 | Mersana Therapeutics, Inc. | Conjugués anticorps-médicament comprenant des agonistes de sting |
WO2021202984A1 (fr) * | 2020-04-02 | 2021-10-07 | Mersana Therapeutics, Inc. | Conjugués anticorps-médicament comprenant des agonistes de sting |
WO2021206158A1 (fr) | 2020-04-10 | 2021-10-14 | 小野薬品工業株式会社 | Méthode de cancérothérapie |
WO2021216572A1 (fr) | 2020-04-20 | 2021-10-28 | Massachusetts Institute Of Technology | Compositions lipidiques pour l'administration de composés agonistes de sting et leurs utilisations |
WO2021232019A1 (fr) | 2020-05-15 | 2021-11-18 | Immunesensor Therapeutics, Inc. | Polythérapies à agoniste de sting assorties d'inhibiteurs de points de contrôle immunitaires |
WO2022097117A1 (fr) | 2020-11-09 | 2022-05-12 | Takeda Pharmaceutical Company Ltd. | Conjugués anticorps-médicament |
US11725024B2 (en) | 2020-11-09 | 2023-08-15 | Takeda Pharmaceutical Company Limited | Antibody drug conjugates |
JP7397996B2 (ja) | 2020-11-09 | 2023-12-13 | 武田薬品工業株式会社 | 抗体薬物コンジュゲート |
WO2022217022A1 (fr) | 2021-04-10 | 2022-10-13 | Profoundbio Us Co. | Agents de liaison à folr1, conjugués de ceux-ci et leurs procédés d'utilisation |
WO2022223619A1 (fr) | 2021-04-20 | 2022-10-27 | Institut Curie | Compositions et procédés destinés à être utilisés en immunothérapie |
WO2022226317A1 (fr) | 2021-04-23 | 2022-10-27 | Profoundbio Us Co. | Anticorps anti-cd70, leurs conjugués et leurs procédés d'utilisation |
WO2023280227A2 (fr) | 2021-07-06 | 2023-01-12 | Profoundbio Us Co. | Lieurs, lieurs de médicament, conjugués de ceux-ci et leurs méthodes d'utilisation |
WO2023004440A2 (fr) | 2021-07-23 | 2023-01-26 | Immunesensor Therapeutics, Inc. | Polythérapies à base d'agonistes de sting comprenant des cytokines |
WO2023109942A1 (fr) * | 2021-12-17 | 2023-06-22 | Jacobio Pharmaceuticals Co., Ltd. | Constructions lieurs-composés comprenant de nouveaux composés utiles en tant qu'agonistes de sting et leurs utilisations |
WO2024020164A2 (fr) | 2022-07-21 | 2024-01-25 | Firefly Bio, Inc. | Agonistes du récepteur des glucocorticoïdes et leurs conjugués |
Also Published As
Publication number | Publication date |
---|---|
JP2020517700A (ja) | 2020-06-18 |
CN110799218A (zh) | 2020-02-14 |
EP3615080A1 (fr) | 2020-03-04 |
AR113224A1 (es) | 2020-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018200812A1 (fr) | Conjugués d'anticorps comprenant un agoniste de sting | |
US20210346387A1 (en) | Antibody conjugates comprising toll-like receptor agonist | |
US20200164084A1 (en) | Antibody conjugates comprising toll-like receptor agonist and combination therapies | |
US20210170043A1 (en) | Dc-sign antibody conjugates comprising sting agonists | |
CA3165399A1 (fr) | Utilisations d'anticorps anti-tgf-betas et inhibiteurs de point de controle pour le traitement des maladies proliferatives | |
US20230053449A1 (en) | Dc-sign antibody drug conjugates | |
WO2020089815A1 (fr) | Conjugués d'anticorps comprenant un agoniste de sting | |
US11701427B2 (en) | Diels-alder conjugation methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18724677 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2019558397 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2018724677 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2018724677 Country of ref document: EP Effective date: 20191128 |